2020 SGO实践声明:卵巢癌前线PARP抑制剂维持治疗

2020-08-07 美国妇科肿瘤学会 Gynecol Oncol . 2020 Aug 7;

2020年8月,美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容

中文标题:

2020 SGO实践声明:卵巢癌前线PARP抑制剂维持治疗

英文标题:

Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement

发布机构:

美国妇科肿瘤学会

发布日期:

2020-08-07

简要介绍:

2020年8月,美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容提供循证决策。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 SGO实践声明:卵巢癌前线PARP抑制剂维持治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ef9321c00195a15f, title=2020 SGO实践声明:卵巢癌前线PARP抑制剂维持治疗 , enTitle=Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement, guiderFrom=Gynecol Oncol . 2020 Aug 7;, authorId=0, author=, summary=2020年8月,美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容, cover=https://img.medsci.cn/2020817/1597678583548_2020535.jpg, journalId=0, articlesId=null, associationId=1177, associationName=美国妇科肿瘤学会, associationIntro=The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women&rsquo;s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations., copyright=0, guiderPublishedTime=Fri Aug 07 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月,美国妇科肿瘤学会(SGO)发布了卵巢癌前线PARP抑制剂维持治疗的实践声明。PARP抑制剂在卵巢癌的治疗中显示出一定的活性。本文主要针对卵巢癌初始维持治疗中应用PARP抑制剂的相关内容提供循证决策。</p> </div> </div> </div>, tagList=[TagDto(tagId=359, tagName=卵巢癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21052, categoryName=梅斯医学-卵巢癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=359, guiderKeyword=卵巢癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5421, appHits=127, showAppHits=0, pcHits=662, showPcHits=5294, likes=1, shares=5, comments=4, approvalStatus=1, publishedTime=Mon Aug 17 23:41:12 CST 2020, publishedTimeString=2020-08-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 17 23:36:28 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 17:03:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SGO实践声明:卵巢癌前线PARP抑制剂维持治疗.pdf)])
2020 SGO实践声明:卵巢癌前线PARP抑制剂维持治疗.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1011402, encodeId=0b961011402f9, content=特别需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6425439702, createdName=ms6000001372871109, createdTime=Wed Aug 25 16:07:37 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809953, encodeId=41d180995302, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>作用仍很小,仅仅微有提高而已。需要突破性药物问世, beContent=null, objectType=guider, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌), TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Aug 18 07:08:38 CST 2020, time=2020-08-18, status=1, ipAttribution=)]
    2021-08-25 ms6000001372871109

    特别需要

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1011402, encodeId=0b961011402f9, content=特别需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6425439702, createdName=ms6000001372871109, createdTime=Wed Aug 25 16:07:37 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809953, encodeId=41d180995302, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>,<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>作用仍很小,仅仅微有提高而已。需要突破性药物问世, beContent=null, objectType=guider, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌), TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Aug 18 07:08:38 CST 2020, time=2020-08-18, status=1, ipAttribution=)]
    2020-08-18 lovetcm

    #卵巢癌##PARP抑制剂#作用仍很小,仅仅微有提高而已。需要突破性药物问世

    0

拓展阅读

2010ESMO临床实践指南:非上皮性卵巢癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2011 NICE 卵巢癌的诊断和起始治疗

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-01-01

2011 NICE Trabectedin治疗复发性卵巢癌

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-01-01

2012 ESMO临床实践指南:非上皮性卵巢癌的诊治与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2012 NSGC实践指南:遗传性乳腺癌和卵巢癌的风险评估和遗传咨询

国家遗传咨询师学会(NSGC,National Society of Genetic Counselors) · 2012-11-28

2013 FIGO 卵巢癌、输卵管癌、腹膜癌分期指南

国际妇产科联盟(FIGO,International Federation of Gynecology and Obstetrics) · 2013-10-22